Silvestrol aglycone has shown potential in cancer research due to its ability to inhibit protein synthesis in cancer cells. It targets the eIF4A RNA helicase, which is crucial for the translation of certain oncoproteins, thereby suppressing tumor growth. This compound is being studied for its efficacy in treating various cancers, including leukemia, breast cancer, and lung cancer, particularly those resistant to conventional therapies. Additionally, its role in enhancing the effectiveness of other chemotherapeutic agents is under investigation, making it a promising candidate for combination therapies. Preliminary studies also indicate potential in treating certain viral infections by inhibiting viral replication. Research is ongoing to explore its full therapeutic potential, confirm efficacy and safety in humans, and develop derivatives with improved pharmacological properties.